{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:55:20Z","timestamp":1795042520477,"version":"4.10.2"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000062","name":"U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK113191"],"award-info":[{"award-number":["R01DK113191"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acute kidney injury is common among hospitalized individuals, particularly those exposed to certain medications, and is associated with substantial morbidity and mortality. In a pragmatic, open-label, National Institutes of Health-funded, parallel group randomized controlled trial (clinicaltrials.gov NCT02771977), we investigate whether an automated clinical decision support system affects discontinuation rates of potentially nephrotoxic medications and improves outcomes in patients with AKI. Participants included 5060 hospitalized adults with AKI and an active order for any of three classes of medications of interest: non-steroidal anti-inflammatory drugs, renin-angiotensin-aldosterone system inhibitors, or proton pump inhibitors. Within 24\u2009hours of randomization, a medication of interest was discontinued in 61.1% of the alert group versus 55.9% of the usual care group (relative risk 1.08, 1.04 \u2013 1.14, p\u2009=\u20090.0003). The primary outcome \u2013 a composite of progression of acute kidney injury, dialysis, or death within 14 days - occurred in 585 (23.1%) of individuals in the alert group and 639 (25.3%) of patients in the usual care group (RR 0.92, 0.83 \u2013 1.01, p\u2009=\u20090.09). Trial Registration Clinicaltrials.gov NCT02771977.<\/jats:p>","DOI":"10.1038\/s41467-023-38532-3","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T14:03:14Z","timestamp":1684332194000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["A randomized clinical trial assessing the effect of automated medication-targeted alerts on acute kidney injury outcomes"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2633-2412","authenticated-orcid":false,"given":"F. Perry","family":"Wilson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8323-8676","authenticated-orcid":false,"given":"Yu","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Coronel-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abinet","family":"Aklilu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lama","family":"Ghazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason H.","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Latham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3919-1871","authenticated-orcid":false,"given":"Hannah","family":"Melchinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry G.","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9537-9038","authenticated-orcid":false,"given":"Dennis G.","family":"Moledina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9051-7385","authenticated-orcid":false,"given":"Chirag R.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Partridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Testani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugochukwu","family":"Ugwuowo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"38532_CR1","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00134-015-3934-7","volume":"41","author":"EAJ Hoste","year":"2015","unstructured":"Hoste, E. A. J. et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 41, 1411\u20131423 (2015).","journal-title":"Intensive Care Med."},{"key":"38532_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.12788\/jhm.2683","volume":"12","author":"SA Silver","year":"2017","unstructured":"Silver, S. A., Long, J., Zheng, Y. & Chertow, G. M. Cost of acute kidney injury in hospitalized patients. J. Hosp. Med. 12, 70\u201376 (2017).","journal-title":"J. Hosp. Med."},{"key":"38532_CR3","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.2215\/CJN.07920713","volume":"9","author":"A Wonnacott","year":"2014","unstructured":"Wonnacott, A., Meran, S., Amphlett, B., Talabani, B. & Phillips, A. Epidemiology and outcomes in community-acquired versus hospital-acquired AKI. Clin. J. Am. Soc. Nephrol. 9, 1007\u20131014 (2014).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"38532_CR4","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/ki.2011.379","volume":"81","author":"SG Coca","year":"2012","unstructured":"Coca, S. G., Singanamala, S. & Parikh, C. R. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 81, 442\u2013448 (2012).","journal-title":"Kidney Int."},{"key":"38532_CR5","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3390\/jcm8091323","volume":"8","author":"I Acosta-Ochoa","year":"2019","unstructured":"Acosta-Ochoa, I., Bustamante-Munguira, J., Mendiluce-Herrero, A., Bustamante-Bustamante, J. & Coca-Rojo, A. Impact on outcomes across KDIGO-2012 AKI criteria according to baseline renal function. J. Clin. Med. 8, 1323 (2019).","journal-title":"J. Clin. Med."},{"key":"38532_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2215\/CJN.02730313","volume":"9","author":"X Zeng","year":"2014","unstructured":"Zeng, X., McMahon, G. M., Brunelli, S. M., Bates, D. W. & Waikar, S. S. Incidence, outcomes, and comparisons across definitions of AKI in hospitalized individuals. Clin. J. Am. Soc. Nephrol. 9, 12\u201320 (2014).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"38532_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1681\/ASN.2007080837","volume":"20","author":"A Ishani","year":"2009","unstructured":"Ishani, A. et al. Acute kidney injury increases risk of ESRD among elderly. J. Am. Soc. Nephrol. 20, 223\u2013228 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"38532_CR8","doi-asserted-by":"publisher","first-page":"f4930","DOI":"10.1136\/bmj.f4930","volume":"347","author":"S Ftouh","year":"2013","unstructured":"Ftouh, S. & Thomas, M. Acute kidney injury: summary of NICE guidance. BMJ 347, f4930 (2013).","journal-title":"BMJ"},{"key":"38532_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.1","volume":"2","author":"JA Kellum","year":"2012","unstructured":"Kellum, J. A. et al. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int. Suppl. 2, 1\u2013138 (2012).","journal-title":"Kidney Int. Suppl."},{"key":"38532_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1159\/000371748","volume":"41","author":"N Srisawat","year":"2015","unstructured":"Srisawat, N. et al. Variation in risk and mortality of acute kidney injury in critically Ill patients: a multicenter study. Am. J. Nephrol. 41, 81\u201388 (2015).","journal-title":"Am. J. Nephrol."},{"key":"38532_CR11","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1053\/j.ajkd.2011.07.022","volume":"58","author":"D Tawadrous","year":"2011","unstructured":"Tawadrous, D. et al. Use of clinical decision support systems for kidney-related drug prescribing: a systematic review. Am. J. Kidney Dis. 58, 903\u2013914 (2011).","journal-title":"Am. J. Kidney Dis."},{"key":"38532_CR12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.7861\/clinmedicine.13-3-233","volume":"13","author":"S Finlay","year":"2013","unstructured":"Finlay, S. et al. Identification of risk factors associated with acute kidney injury in patients admitted to acute medical units. Clin. Med. 13, 233 (2013).","journal-title":"Clin. Med."},{"key":"38532_CR13","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1053\/j.ajkd.2020.08.013","volume":"77","author":"DG Moledina","year":"2021","unstructured":"Moledina, D. G. et al. Variation in best practice measures in patients with severe hospital-acquired acute kidney injury: a multicenter study. Am. J. Kidney Dis. J. Natl Kidney Found. 77, 547\u2013549 (2021).","journal-title":"Am. J. Kidney Dis. J. Natl Kidney Found."},{"key":"38532_CR14","doi-asserted-by":"publisher","first-page":"e2645","DOI":"10.1097\/MD.0000000000002645","volume":"95","author":"CI Chou","year":"2016","unstructured":"Chou, C. I. et al. Adverse effects of oral nonselective and cyclooxygenase-2-selective NSAIDs on hospitalization for acute kidney injury: a nested case\u2013control cohort study. Medicine 95, e2645 (2016).","journal-title":"Medicine"},{"key":"38532_CR15","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/pds.1798","volume":"18","author":"JP Lafrance","year":"2009","unstructured":"Lafrance, J. P. & Miller, D. R. Selective and non-selective non-steroidal anti-inflammatory drugs and the risk of acute kidney injury. Pharmacoepidemiol. Drug Saf. 18, 923\u2013931 (2009).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"38532_CR16","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3389\/fped.2019.00520","volume":"7","author":"S Clav\u00e9","year":"2019","unstructured":"Clav\u00e9, S., Rousset-Rouvi\u00e8re, C., Daniel, L. & Tsimaratos, M. The invisible threat of non-steroidal anti-inflammatory drugs for kidneys. Front Pediatr. 7, 520 (2019).","journal-title":"Front Pediatr."},{"key":"38532_CR17","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.2215\/CJN.05271107","volume":"3","author":"P Arora","year":"2008","unstructured":"Arora, P. et al. Preoperative use of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers is associated with increased risk for acute kidney injury after cardiovascular surgery. Clin. J. Am. Soc. Nephrol. 3, 1266\u20131273 (2008).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"38532_CR18","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/jch.12795","volume":"18","author":"M Chaumont","year":"2016","unstructured":"Chaumont, M. et al. Acute kidney injury in elderly patients with chronic kidney disease: do angiotensin-converting enzyme inhibitors carry a risk? J. Clin. Hypertens. 18, 514\u2013521 (2016).","journal-title":"J. Clin. Hypertens."},{"key":"38532_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2215\/CJN.05800519","volume":"15","author":"Cyuan Hsu","year":"2020","unstructured":"Hsu, Cyuan et al. Renin-angiotensin system blockade after acute kidney injury (AKI) and risk of recurrent AKI. Clin. J. Am. Soc. Nephrol. 15, 26\u201334 (2020).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"38532_CR20","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1001\/jamainternmed.2018.4749","volume":"178","author":"S Brar","year":"2018","unstructured":"Brar, S. et al. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with outcomes after acute kidney injury. JAMA Intern. Med. 178, 1681\u20131690 (2018).","journal-title":"JAMA Intern. Med."},{"key":"38532_CR21","doi-asserted-by":"crossref","unstructured":"Tomson, C. & Tomlinson, L. A. Stopping RAS inhibitors to minimize AKI: more harm than good? Clin. J. Am. Soc. Nephrol. 14, 617 (2019).","DOI":"10.2215\/CJN.14021118"},{"key":"38532_CR22","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","volume":"176","author":"B Lazarus","year":"2016","unstructured":"Lazarus, B. et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern. Med. 176, 238\u2013246 (2016).","journal-title":"JAMA Intern. Med."},{"key":"38532_CR23","doi-asserted-by":"publisher","first-page":"E166","DOI":"10.9778\/cmajo.20140074","volume":"3","author":"T Antoniou","year":"2015","unstructured":"Antoniou, T. et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study. CMAJ Open 3, E166\u2013E171 (2015).","journal-title":"CMAJ Open"},{"key":"38532_CR24","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.2147\/DDDT.S130568","volume":"11","author":"Y Yang","year":"2017","unstructured":"Yang, Y. et al. Proton-pump inhibitors use, and risk of acute kidney injury: a meta-analysis of observational studies. Drug Des. Devel. Ther. 11, 1291 (2017).","journal-title":"Drug Des. Devel. Ther."},{"key":"38532_CR25","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/phar.2235","volume":"39","author":"E Hart","year":"2019","unstructured":"Hart, E., Dunn, T. E., Feuerstein, S. & Jacobs, D. M. Proton pump inhibitors and risk of acute and chronic kidney disease: a retrospective cohort study. Pharmacother. J. Hum. Pharm. Drug Ther. 39, 443\u2013\u2212453 (2019).","journal-title":"Pharmacother. J. Hum. Pharm. Drug Ther."},{"key":"38532_CR26","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40620-016-0309-2","volume":"29","author":"DG Moledina","year":"2016","unstructured":"Moledina, D. G. & Perazella, M. A. PPIs and kidney disease: from AIN to CKD. J. Nephrol. 29, 611\u2013616 (2016).","journal-title":"J. Nephrol."},{"key":"38532_CR27","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.2169\/internalmedicine.49.4064","volume":"49","author":"SM Eid","year":"2010","unstructured":"Eid, S. M. et al. Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists. Intern. Med. 49, 2561\u20132568 (2010).","journal-title":"Intern. Med."},{"key":"38532_CR28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.20452\/pamw.2790","volume":"125","author":"D Ksi\u0105dzyna","year":"2015","unstructured":"Ksi\u0105dzyna, D., Szel\u0105g, A. & Paradowski, L. Overuse of proton pump inhibitors. Pol. Arch. Med Wewn. 125, 289\u2013298 (2015).","journal-title":"Pol. Arch. Med Wewn."},{"key":"38532_CR29","doi-asserted-by":"publisher","first-page":"288","DOI":"10.2174\/157488410793352067","volume":"5","author":"E Ramirez","year":"2010","unstructured":"Ramirez, E. et al. Overuse of PPIs in patients at admission, during hospitalisation, and at discharge in a terciary Spanish hospital. Curr. Clin. Pharm. 5, 288\u2013297 (2010).","journal-title":"Curr. Clin. Pharm."},{"key":"38532_CR30","doi-asserted-by":"crossref","unstructured":"Wilson, F. P. et al. Automated, electronic alerts for acute kidney injury: a single-blind, parallel-group, randomised controlled trial. Lancet 385, 1966\u20131974 (2015).","DOI":"10.1016\/S0140-6736(15)60266-5"},{"key":"38532_CR31","doi-asserted-by":"publisher","first-page":"m4786","DOI":"10.1136\/bmj.m4786","volume":"372","author":"FP Wilson","year":"2021","unstructured":"Wilson, F. P. et al. Electronic health record alerts for acute kidney injury: multicenter, randomized clinical trial. BMJ 372, m4786 (2021).","journal-title":"BMJ"},{"key":"38532_CR32","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1681\/ASN.2018090886","volume":"30","author":"NM Selby","year":"2019","unstructured":"Selby, N. M. et al. An organizational-level program of intervention for AKI: a pragmatic stepped wedge cluster randomized trial. J. Am. Soc. Nephrol. 30, 505\u2013515 (2019).","journal-title":"J. Am. Soc. Nephrol."},{"key":"38532_CR33","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.kint.2019.10.015","volume":"97","author":"SL Goldstein","year":"2020","unstructured":"Goldstein, S. L. et al. A prospective multi-center quality improvement initiative (NINJA) indicates a reduction in nephrotoxic acute kidney injury in hospitalized children. Kidney Int. 97, 580\u2013588 (2020).","journal-title":"Kidney Int."},{"key":"38532_CR34","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/ndt\/gfx149.SP428","volume":"32","author":"P Lachance","year":"2017","unstructured":"Lachance, P. et al. Association between e-alert implementation for detection of acute kidney injury and outcomes: a systematic review. Nephrol. Dial. Transpl. 32, 265\u2013272 (2017).","journal-title":"Nephrol. Dial. Transpl."},{"key":"38532_CR35","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1681\/ASN.2017070765","volume":"29","author":"M Al-Jaghbeer","year":"2018","unstructured":"Al-Jaghbeer, M., Dealmeida, D., Bilderback, A., Ambrosino, R. & Kellum, J. A. Clinical decision support for in-hospital AKI. J. Am. Soc. Nephrol. 29, 654\u2013660 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"38532_CR36","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/jgh.15151","volume":"36","author":"G Chen","year":"2021","unstructured":"Chen, G. et al. Acute kidney injury following the use of different proton pump inhibitor regimens: a real-world analysis of post-marketing surveillance data. J. Gastroenterol. Hepatol. 36, 156\u2013162 (2021).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"38532_CR37","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1002\/pds.3329","volume":"21","author":"CE Leonard","year":"2012","unstructured":"Leonard, C. E. et al. Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury. Pharmacoepidemiol. Drug Saf. 21, 1155\u20131172 (2012).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"38532_CR38","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1681\/ASN.2016020192","volume":"27","author":"DG Moledina","year":"2016","unstructured":"Moledina, D. G. & Perazella, M. A. Proton pump inhibitors and CKD. J. Am. Soc. Nephrol. 27, 2926\u20132928 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"38532_CR39","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1053\/j.jvca.2020.03.031","volume":"34","author":"B Milne","year":"2020","unstructured":"Milne, B., Gilbey, T., Ostermann, M. & Kunst, G. Pro: we should stop ACE inhibitors early before cardiac surgery to prevent postoperative acute kidney injury. J. Cardiothorac. Vasc. Anesth. 34, 2832\u20132835 (2020).","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"38532_CR40","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1053\/j.jvca.2020.03.025","volume":"34","author":"DK Tempe","year":"2020","unstructured":"Tempe, D. K. & Hasija, S. Con: does preoperative discontinuation of angiotensin-converting enzyme inhibitors\/angiotensin II receptor blockers reduce postoperative acute kidney injury. J. Cardiothorac. Vasc. Anesth. 34, 2836\u20132838 (2020).","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"38532_CR41","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/bmj.322.7282.355","volume":"322","author":"DJ Torgerson","year":"2001","unstructured":"Torgerson, D. J. Contamination in trials: is cluster randomisation the answer. BMJ 322, 355\u2013357 (2001).","journal-title":"BMJ"},{"key":"38532_CR42","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1002\/sim.8958","volume":"40","author":"K Hemming","year":"2021","unstructured":"Hemming, K., Taljaard, M., Moerbeek, M. & Forbes, A. Contamination: How much can an individually randomized trial tolerate. Stat. Med. 40, 3329\u20133351 (2021).","journal-title":"Stat. Med."},{"key":"38532_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-018-0876-7","volume":"19","author":"S Mehta","year":"2018","unstructured":"Mehta, S. et al. The prognostic importance of duration of AKI: a systematic review and meta-analysis. BMC Nephrol. 19, 1\u201310. (2018).","journal-title":"BMC Nephrol."},{"key":"38532_CR44","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1002\/sim.4780091207","volume":"9","author":"IK Hwang","year":"1990","unstructured":"Hwang, I. K., Shih, W. J. & De Cani, J. S. Group sequential designs using a family of type I error probability spending functions. Stat. Med 9, 1439\u20131445 (1990).","journal-title":"Stat. Med"},{"key":"38532_CR45","doi-asserted-by":"publisher","unstructured":"Wilson, Francis. Automated, medication-targeted alerts for Acute Kidney Injury \u2013 A randomized trial, Dryad, Dataset, https:\/\/doi.org\/10.5061\/dryad.kh189327p (2023).","DOI":"10.5061\/dryad.kh189327p"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-38532-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-38532-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-38532-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T15:23:51Z","timestamp":1729437831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-38532-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,17]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["38532"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-38532-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,17]]},"assertion":[{"value":"8 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Competing interests: All authors have completed the ICMJE uniform disclosure form and declare: F.P.W. recognizes support from R01DK113191, R01HS027626 and P30DK079310, D.G.M. received support from National Institutes of Health awards K23DK117065 and R01DK128087, and C.R.P. is supported by NIH grants R01HL085757; J.M.T. reports grants and\/or personal fees from 3ive labs, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Astra Zeneca, Novartis, Cardionomic, MagentaMed, Reprieve inc., FIRE1, W.L. Gore, Sanofi, Sequana Medical, Otsuka, Abbott, Merck, Windtree Therapeutics, Lexicon pharmaceuticals, Precardia, Relypsa, Regeneron, BD, Edwards life sciences, and Lilly; D.G.M. and C.R.P. are co-inventors of the pending patent application \u201cMethods and Systems for Diagnosis of Acute Interstitial Nephritis\u201d. C.R.P. is a member of the advisory board of and owns equity in RenalytixAI. He also serves as a consultant for Genfit and Novartis. In addition, J.M.T. has a patent Treatment of diuretic resistance issued to Yale and Corvidia Therapeutics Inc, a patent Methods for measuring renalase issued to Yale, and a patent Treatment of diuretic resistance pending with Reprieve inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2826"}}